The expansion includes new products under its Redecan and Good Supply brands, aimed at enhancing treatment options for healthcare professionals and patients.This initiative underscores Tilray’s commitment to the Australian market, a key growth area, according to Rajnish Ohri, President of International at Tilray Brands. The expanded portfolio will offer medical cannabis flower, extracts, vapes, and pastilles, enhancing access to high-potency, patient-focused solutions.While the broader market is down, with ...

NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), today announced its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces Tilray Medical’s long-term commitment to the Australian market and supports increased patient access to regulated, clinically supported medical cannabis products. Tilray Medical has operated in Aus ...

Core Insights - iAnthus Capital Holdings, Inc. is making significant progress in retail expansion, brand development, and capital structure initiatives in the cannabis industry [1] Retail Expansion - The Company plans to open its 26th GrowHealthy dispensary in Tequesta, Florida, on or about March 27, 2026, pending regulatory approvals, to enhance patient access in Palm Beach County [2] - The Tequesta dispensary aims to provide convenient access to high-quality cannabis products and is designed to meet the diverse wellness needs of the local community [3][4] Brand Development - In New Jersey, iAnthus has expanded its brand, The Vault, which features a curated archive of cannabis genetics aimed at resonating with distinct consumer segments [5] Capital Structure Initiatives - iAnthus, along with its subsidiary iAnthus New Jersey, LLC, has entered into amending agreements with related-party lenders to amend the terms of senior secured bridge notes issued on February 2, 2021 [6] - The maturity date of the Bridge Notes has been extended from February 16, 2026, to June 24, 2027, with an amendment fee of 2% of the principal amount, which is approximately US$8.4 million as of February 16, 2026 [7][8]

Core Insights - Gotham has launched the Gotham Growth Project (GGP), a business accelerator aimed at supporting cannabis consumer brands from underserved communities, with an initial focus on Black-owned businesses in New York City [1][4] Group 1: Program Overview - GGP provides hands-on business strategy and mentorship to help founders build sustainable cannabis businesses [1] - The program includes six focused sessions covering various aspects of business development [2][6] - The program will conclude with a live pitch showcase at Gotham's semiannual leadership conference in October [3] Group 2: Program Objectives and Structure - The mission of GGP is to assist founders in transitioning from traction to scalability, addressing the challenges faced by diverse entrepreneurs [2] - Founders will engage in a curriculum that combines expert instruction, peer collaboration, and practical assignments to tackle real-world business challenges [3] Group 3: Eligibility and Application - Eligible applicants must be at least 51% Black-owned, have been in business for at least one year, and have at least one product on the market [5] - Applications are currently open and will close on March 11 at 5:00 p.m. ET [5]

Core Viewpoint - A potential U.S. move to block imports of certain disposable vapes could reduce the unregulated e-cigarette market by up to one-third, according to British American Tobacco's CEO, although any significant impact is not expected before 2027 [1]. Group 1: Market Impact - The unregulated e-cigarette devices account for approximately 70% of U.S. e-cigarette sales, adversely affecting both vape and traditional tobacco businesses [1]. - A block on imports could lead to a decline in industry sales to below 50%, equating to a reduction of roughly one-third [1]. - The CEO indicated that the scale of the impact is difficult to predict due to existing supply chains and large inventories that would delay effects [1]. Group 2: Regulatory Developments - British American Tobacco has two active cases at the U.S. International Trade Commission (ITC) aimed at blocking imports of unregulated devices [1]. - An ITC judge previously ruled in favor of BAT in a patent dispute, recommending a general exclusion order against disposable vapes infringing its patents [1]. - A full ITC determination is expected in March, followed by a 60-day presidential review [1]. Group 3: Future Considerations - The CEO suggested that the U.S. Food and Drug Administration (FDA) may initiate a program to explore different approaches to vapes, potentially including flavored options [1]. - The FDA has been looking to expedite or streamline its processes after years of rejecting most applications for new nicotine products [1].

Financial Data and Key Metrics Changes - Canopy Growth ended Q3 with CAD 371 million in cash and cash equivalents, and a net cash position of CAD 146 million, marking a strong financial foundation [4][10] - The company achieved its slimmest Adjusted EBITDA loss to date of CAD 3 million, reflecting improved cost discipline and execution [14] - Q3 cannabis net revenue was CAD 52 million, up 4% year-over-year, with Canadian medical cannabis revenue increasing 15% to CAD 23 million [11][12] Business Line Data and Key Metrics Changes - Canadian medical cannabis net revenue grew 15% year-over-year, marking the sixth consecutive quarter of growth, driven by high-quality patient experiences and engagement [6] - Canadian adult use cannabis revenue increased 8% year-over-year to CAD 23 million, supported by growth in pre-rolls and vapes [12] - Storz & Bickel net revenue grew 45% sequentially to CAD 23 million, driven by strong seasonal sales and the introduction of new products [13] Market Data and Key Metrics Changes - International cannabis sales increased 22% quarter-over-quarter, indicating stabilization and return to growth [12] - The company is focusing on improving execution and laying groundwork for growth in international markets, particularly in Europe [8] Company Strategy and Development Direction - Canopy Growth is focused on elevating the quality of its brands, strengthening product innovation, and improving cultivation efficiency [7][19] - The proposed acquisition of MTL Cannabis is expected to enhance the company's leadership in Canadian medical cannabis and provide high-quality flower supply [5][6] - The company aims to achieve positive Adjusted EBITDA during fiscal 2027, supported by cost-saving initiatives and growth in Canadian cannabis sales [10][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's progress, highlighting a stronger balance sheet and growing Canadian cannabis sales [9] - The focus is on unlocking additional value through elevated cultivation, innovative brands, and disciplined execution [9][19] - Management is actively addressing potential impacts from proposed changes to the Veterans Reimbursement Program while maintaining service quality [6][32] Other Important Information - The company completed a CAD 150 million recapitalization to improve liquidity and extend debt maturities to 2031, providing more flexibility for future financing [5][11] - The integration of MTL Cannabis is expected to contribute positively to net revenue, gross margin, and Adjusted EBITDA [16] Q&A Session Summary Question: Expectations for international business growth over the next 12-18 months - Management indicated that they are confident in improving international supply chain capabilities and expanding flower offerings in Europe [21][22] Question: Trends in gross margin expectations for cannabis - Management expects a blended gross margin in the mid- to high 30s, with the MTL acquisition anticipated to be accretive to gross margin [25][26] Question: Clarification on positive Adjusted EBITDA expectations - Management aims for positive Adjusted EBITDA during fiscal 2027, with efforts to achieve this as soon as possible [29] Question: Impact of debt maturities and equity issuance - Management expects reduced utilization of the ATM in the coming quarters due to improved balance sheet position [30] Question: Domestic medical business and veterans reimbursement proposal - Management is actively working to mitigate the impact of proposed reimbursement changes on veterans while maintaining service quality [32][34]

Industry Overview - The U.S. cannabis sector is at a critical inflection point as of February 2026, with improved market sentiment but selective investor interest [1] - Long-term demand for cannabis continues to grow despite price volatility, with state-level legalization expanding and medical programs remaining stable [2] - Profitability is now prioritized over rapid expansion, leading companies to tighten operations and protect margins [3] Company Highlights Trulieve Cannabis Corp. (TCNNF) - Trulieve is a dominant cannabis operator in the U.S., operating a vertically integrated business model across cultivation, processing, distribution, and retail sales [4] - The company has a significant presence in Florida, which serves as its core revenue engine, while also expanding into states like Pennsylvania, Arizona, Maryland, Ohio, and Connecticut [5] - As of early 2026, Trulieve operates over 230 dispensaries nationwide, enhancing brand visibility and customer loyalty [7] - The company focuses on disciplined expansion, targeting profitable markets to remain competitive during industry slowdowns [9] - Financially, Trulieve emphasizes cash flow and balance sheet strength, with stable revenue and healthy gross margins despite pricing pressure [10] - Management has taken steps to address near-term debt obligations, improving liquidity and reducing financial risk [11] - Trulieve continues generating meaningful EBITDA and maintains sufficient cash reserves for selective growth [12] - The company is well-positioned for future growth as regulatory clarity improves [13] Curaleaf Holdings, Inc. (CURLF) - Curaleaf is the largest cannabis company in the U.S. by revenue, operating across numerous states and markets, providing diversification and risk mitigation [13] - The company operates over 160 dispensaries, with a significant retail presence in Florida and strong positions in New Jersey, New York, Arizona, and Illinois [14] - Curaleaf focuses on operational efficiency, optimizing existing assets rather than aggressive expansion, which helps preserve margins [17] - Financially, Curaleaf generates over a billion dollars in annual revenue, with recent trends showing stabilization and improved gross margins [18] - The company is focused on reducing expenses and streamlining operations, with debt management being a priority [19] - While net profitability remains elusive, losses have narrowed, reflecting disciplined spending and operational focus [20] Verano Holdings Corp. (VRNOF) - Verano is a vertically integrated cannabis operator with a footprint in key markets such as Illinois, Florida, New Jersey, Pennsylvania, and Arizona [21] - The company operates retail dispensaries under brands like Zen Leaf and MÜV, maintaining a strategically placed retail network [22] - Verano emphasizes product quality and consistent branding to attract loyal customers, balancing retail growth with operational discipline [24] - Financially, Verano has faced revenue pressure but has focused on cost control to protect margins [25] - The company has significant net losses due to ongoing investments and restructuring costs, but prioritizes operational efficiency [26] - Verano is considered a higher-risk, higher-reward operator, with potential upside if market conditions improve [26]

Core Business Performance - The core Canadian retail business demonstrated strength with same-store sales growth of 5.5%, contributing to a 15% year-over-year growth in the brick-and-mortar segment [1] - High Tide added 27 stores in 2025, reaching a total of 218 locations, and plans to add another 20-30 stores in 2026, targeting over 350 locations long-term [7][8] Financial Highlights - Fourth-quarter revenue rose 19% year-over-year and 10% sequentially, primarily driven by the brick-and-mortar segment, with consolidated gross margin at 26% [3] - Record performance was reported with revenue of CAD 164 million and Adjusted EBITDA of CAD 12.4 million, implying an annualized revenue run rate exceeding CAD 650 million [4][8] - Adjusted EBITDA increased by 51% year-over-year and 17% sequentially, with a record Adjusted EBITDA margin of 9.4% in the brick-and-mortar segment [2] Operational Efficiency - Salaries and wages fell to 11.5% of revenue, the lowest level in nine quarters, while general and administrative expenses were 4.3% of revenue [2] - Annualized revenue per square foot was CAD 1,775 in the quarter, with market share across five provinces increasing to 12% from 11% a year earlier [10] Loyalty and Membership Growth - Cabana Club membership reached 2.5 million, up 45% year-over-year, with a long-term target raised to 3 million members [9] - The Canadian ELITE member count reached 151,000, up 107% year-over-year, indicating increased shopping frequency and larger basket sizes among these members [9] Acquisition Impact - The Remaxion acquisition contributed nearly CAD 10 million in revenue but pressured margins due to inventory and expiry issues, with improvements expected by late Q2/Q3 [6][11] - High Tide is diversifying supply routes beyond Portugal, citing new sourcing strategies that could reduce costs by 30%-40% [14] Cash Flow and Balance Sheet - Free cash flow for Q4 was CAD 1.3 million, with a total of CAD 12.12 million for the full fiscal year, supporting internal funding for store expansion [16] - Total debt stood at CAD 65.5 million, with cash and cash equivalents at CAD 47.9 million and no upcoming maturities for over two years [17] Market Opportunities - The company is exploring partnerships with U.S. operators following an executive order on cannabis rescheduling, while also considering potential CBD-related policy changes that could benefit its U.S. CBD brands [17][18]

Walgreens has started selling vapes in some stores across the US, a surprise reversal after the drugstore chain stopped selling them more than six years ago amid concerns about their popularity with teens. https://t.co/FZ1TsQG6o8 ...

Core Viewpoint - Ascend Wellness Holdings, Inc. has opened a new dispensary in Englewood, Ohio, expanding its retail presence in the state's regulated cannabis market, catering to both medical and non-medical customers [1][2]. Group 1: Company Expansion - The new dispensary in Englewood is part of Ascend's strategy to enhance its retail footprint in Ohio, where it already operates multiple locations [2]. - Ascend aims to provide safe access and quality products while focusing on a patient- and customer-centric retail experience [2]. Group 2: Grand Opening and Community Engagement - A grand opening event is scheduled for January 16, inviting local patients, customers, and community members to explore the new facility and learn about Ascend's product offerings [3]. - The dispensary is designed to create an efficient and welcoming shopping experience, featuring a variety of cannabis products from leading brands [4]. Group 3: Product Offering and Customer Engagement - The Englewood dispensary will offer a wide range of cannabis products, including flower, vapes, edibles, and concentrates, with options for in-store or online purchases [4]. - Ascend has introduced a revamped loyalty program, the Ascenders Club, to reward customers for their purchases and in-store deals [5]. Group 4: Operational Details - The Englewood dispensary will operate daily from 8:00 a.m. to 11:00 p.m., serving both medical and non-medical customers [6]. - For further information about Ascend and its dispensaries, customers can visit the company's website [6]. Group 5: Company Overview - Ascend Wellness Holdings, Inc. is a vertically integrated cannabis operator with assets across several states, including Ohio, and produces a curated selection of cannabis products for retail and wholesale [7].